United Therapeutics Launches $477.6M Accelerated Share Repurchase, Completing $2B Authorization
UTHR sits 28% above its 52-week low of $388.73.
Summary
United Therapeutics entered into a $477.6 million accelerated share repurchase agreement with Citibank, using the remainder of its $2 billion authorization. The company will receive an initial delivery of approximately 719,376 shares, with final settlement expected in Q4 2026.
Key Events · Financing and Capital Events · UTHR
-
ASR Agreement with Citibank
United Therapeutics entered into an accelerated share repurchase agreement with Citibank for approximately $477.6 million, representing the remainder of its $2 billion share repurchase authorization.
-
Initial Share Delivery
The company will make an upfront payment of approximately $477.6 million on or around September 10, 2026, and receive an initial delivery of approximately 719,376 shares, representing about 75% of the total anticipated repurchase.
-
Final Settlement Timing
Final settlement of the ASR is expected to be completed in the fourth quarter of 2026, with the exact number of shares determined by the volume-weighted average price during the term, less a discount.
-
Management Commentary
CEO Martine Rothblatt stated the market is not yet reflecting the company's growth potential, citing multiple inflection points beginning as soon as next year, and noted the company will have returned $4 billion to shareholders in approximately 2.5 years upon completion.
Analysis · UTHR · Life Sciences
United Therapeutics is deploying the remaining $477.6 million of its $2 billion buyback authorization through an accelerated share repurchase with Citibank. The company will pay approximately $477.6 million upfront on September 10, 2026, and receive an initial delivery of about 719,376 shares, representing roughly 75% of the total expected repurchase. Final settlement is expected in Q4 2026. CEO Martine Rothblatt framed the move as a statement that the market is undervaluing the company's growth prospects, citing multiple inflection points beginning as soon as next year. This is a significant capital return event that reduces the share count and signals management's conviction in the stock's value.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UTHR was trading at $497.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.4B. The 52-week trading range was $388.73 to $609.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.